fda glp-1 compounding crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is short-sighted on compounding

Endotoxin also penetrates GAPs, a newly discovered mechanism for the presentation of large molecules to the immune system, in the intestine but not in the colon [53]

10.1016/j.intimp.2009.06.001 Int Immunopharmacol

Description BPC-157 & TB-500 Research Peptide Blend BPC-157 (Pentadecapeptide BPC-157) 10mg and TB-500 10mg (synthetic thymosin beta-4 analog) are laboratory peptides explored separately in preclinical models for roles in tissue protection and repair

Injectable forms are more direct and often used for higher-demand training periods

But coverage for weight-loss drugs expanded much less rapidly than usual